Claims for Patent: 8,470,543

Summary for Patent: 8,470,543

Title:	Methods for differentiating and monitoring parathyroid and bone status related diseases
Abstract:	The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values, one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.
Inventor(s):	Cantor; Thomas L. (El Cajon, CA), Gao; Ping (San Diego, CA)
Assignee:	Scantibodies Laboratory, Inc. (Santee, CA)
Application Number:	13/009,759
Patent Claims:	1. An assay useful for the determination of whole PTH.sub.1-84 while avoiding detection of an interfering non-(1-84) parathyroid hormone fragment utilizing an antibody produced by the following method: a) administering a first peptide or protein immunogen to a host animal to induce antibody production against said first peptide or protein immunogen in said host animal, said first peptide or protein immunogen being human, rat, bovine, or porcine PTH.sub.1-84; b) monitoring antibody titer produced by said administration of said first peptide or protein immunogen to said host animal; c) extracting antiserum produced in said host animal by said administration of said first peptide or protein immunogen; and d) purifying said antiserum and selecting an antibody from said antiserum extracted in step c) by affinity chromatography utilizing a second peptide or protein immunogen, which is human PTH.sub.1-8, rat PTH.sub.1-8, or a peptide having at least four amino acids in the common sequence of human and rat PTH.sub.1-8. 2. The method of claim 1, wherein in step a), the host animal is a goat. 3. The method of claim 1, wherein the first peptide or protein immunogen is human PTH.sub.1-84. 4. The method of claim 1, wherein the first peptide or protein immunogen is rat PTH.sub.1-84. 5. The method of claim 1, wherein the first peptide or protein immunogen is bovine PTH.sub.1-84. 6. The method of claim 1, wherein the first peptide or protein immunogen is porcine PTH.sub.1-84. 7. The method of claim 1, wherein the first peptide or protein immunogen is human PTH.sub.1-84, and the second peptide or protein immunogen is human PTH.sub.1-8. 8. The method of claim 1, wherein the first peptide or protein immunogen is rat PTH.sub.1-84, and the second peptide or protein immunogen is rat PTH.sub.1-8. 9. The method of claim 1, wherein the antibody is a polyclonal antibody. 10. The method of claim 1, wherein the antibody is a monoclonal antibody. 11. The method of claim 1, wherein the antibody further comprises a label. 12. The method of claim 11, wherein the label is selected from the group consisting of a chemiluminescent agent, a colorimetric agent, an energy transfer agent, an enzyme, a fluorescent agent and a radioisotope. 13. The method of claim 1, wherein the antibody is bound to a solid support. 14. The method of claim 1, wherein the solid support is a colloidal solid support or a latex particle. 15. The method of claim 1, wherein the antibody specifically binds to a parathyroid hormone epitope selected from the group consisting of amino acid residues 2-5, 3-6, 4-7, 5-8, 2-6, 3-7 and 4-8 of human PTH.sub.1-84. 16. The method of claim 1, wherein the antibody specifically binds to a parathyroid hormone epitope selected from the group consisting of amino acid residues 2-5, 3-6, 4-7, 5-8, 2-6, 3-7 and 4-8 of rat PTH.sub.1-84. 17. The method of claim 1, wherein the interfering non-(1-84) parathyroid hormone fragment is a peptide having an amino acid sequence from between PTH.sub.3-84 and PTH.sub.34-.sub.84 and functions in vivo as a wPTH antagonist or inhibitor. 18. The method of claim 1, wherein the interfering non-(1-84) parathyroid hormone fragment is PTH.sub.7-84. 19. The method of claim 1, which comprises: a) contacting a sample to be tested; b) allowing the antibody, which is a first antibody, to bind to whole PTH.sub.1-84, if present in the sample, to form a complex; and c) measuring the amount of the complex to measure the amount of whole PTH.sub.1-84 in the sample while not detecting an interfering non-(1-84) parathyroid hormone fragment. 20. The method of claim 19, which further comprises contacting the whole PTH.sub.1-84, if present in the sample, with a second antibody that specifically binds to a portion of the whole PTH.sub.1-84 that does not bind to the first antibody, and the first antibody, whole PTH.sub.1-84, and the second antibody forms a sandwich complex. 21. The method of claim 20, wherein one of the first antibody and the second antibody is labeled. 22. The method of claim 20, wherein one of the first antibody and the second antibody is bound to a solid support. 23. The method of claim 19, wherein the sample is a human sample. 24. The method of claim 19, wherein the sample is a rat sample.

Details for Patent 8,470,543

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2019-01-14